Recombinant Bivalent Live Vectored Vaccine Against Classical Swine Fever and HP-PRRS Revealed Adequate Heterogeneous Protection Against NADC30-Like Strain

Liwei Li, Jinxia Chen, Zhengda Cao, Yunlei Cao, Ziqiang Guo, Tong Wu, Yanjun Zhou, Guoxin Li, Yifeng Jiang, Changlong Liu, Lingxue Yu, Sina Qiao, Jiachen Liu, Guangzhi Tong, Fei GaoFrontiers in Microbiology 2022 · DOI

TL;DR

Researchers have demonstrated that a recombinant bivalent vaccine (rPRRSV-E2) provides significant "cross-protection" against the emerging NADC30-like strain of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). By using a modified live virus backbone to carry antigens for both PRRSV and Classical Swine Fever, this vaccine offers a promising tool for the swine industry to combat genetically diverse and rapidly evolving viral threats.

What Problem Does This Paper Address?

Porcine Reproductive and Respiratory Syndrome (PRRS)—often called "blue ear disease"—is a global economic nightmare for the swine industry, causing reproductive failure in sows and respiratory distress in piglets. The virus responsible (PRRSV) is notorious for its high mutation rate and ability to recombine, leading to a dizzying array of lineages.

In China, the landscape has shifted from "Classical" strains to "Highly Pathogenic" (HP-PRRSV) strains, and most recently, to NADC30-like strains (Lineage 1). These newer strains are particularly troublesome because they frequently swap genetic material with other viruses in the field. Existing commercial vaccines, often based on older lineages, frequently fail to provide adequate protection against these heterologous (genetically different) NADC30-like strains. The authors sought to determine if their bivalent vaccine candidate, designed for HP-PRRSV and Classical Swine Fever (CSF), could stand up to this new challenger.

Methods

The researchers employed a "Trojan Horse" vaccine strategy. They used a modified live virus (MLV) strain of HP-PRRSV (HuN4-F112) as a vector to express the E2 protein of the Classical Swine Fever Virus (CSFV). This creates a bivalent vaccine: one shot protects against two major diseases.

To test its efficacy, they:

  1. Isolated a new strain: They captured a representative NADC30-like strain, dubbed ZJqz21, from a farm in Zhejiang province.
  2. Characterized the enemy: They performed full-genome sequencing and phylogenetic analysis to confirm ZJqz21 belonged to the NADC30-like lineage (Lineage 1.8).
  3. Animal Challenge Model: They divided 15 PRRSV-free piglets into three groups: Vaccinated, Challenge Control (BC), and Mock. The vaccinated group received the rPRRSV-E2 vaccine, and 28 days later, both the vaccinated and BC groups were "challenged" (infected) with the ZJqz21 strain.
  4. Multi-level Evaluation: They monitored rectal temperatures, clinical symptoms (like coughing and lethargy), antibody production via ELISA, and viral loads in blood and tissues using RT-qPCR.

Datasets

While not a "big data" paper in the computational sense, the study relied on:

  • Reference Strains: A collection of 44 representative PRRSV isolates from the GenBank database (listed in Table 1) to build phylogenetic trees.
  • ZJqz21 Genome: The complete 15,042-nucleotide sequence of the newly isolated strain (GenBank accession no. OK274266).
  • Experimental Data: Longitudinal data from the 15-piglet challenge model, including temperature logs and viral titration curves.

Key Insights and Ideas

  • The Power of Heterogeneous Protection: The most significant finding is that a vaccine based on a Lineage 8 backbone (HP-PRRSV) provided "adequate" protection against a Lineage 1 strain (NADC30-like). Despite only sharing ~90% nucleotide identity, the vaccine primed the immune system well enough to recognize the distant relative.
  • Bivalency without Interference: The vaccine successfully induced high titers of antibodies for both PRRSV and CSFV. Often, combining vaccines can lead to "interference" where one component weakens the response to the other; that was not observed here.
  • Shedding Inhibition: Beyond just keeping the pigs alive, the vaccine significantly reduced "viral shedding" (the virus exiting the pig via nasal or anal routes). This is crucial for stopping the spread of the virus within a barn.

Key Results

  • Clinical Relief: While the control group suffered from persistent high fever (reaching 41.2°C) and severe respiratory distress, the vaccinated group showed only mild, transient symptoms.
  • Viral Load Reduction: Vaccination significantly inhibited the viral load in target tissues like the lungs, tonsils, and lymph nodes.
  • Pathology: Histological exams showed that vaccinated pigs had much milder interstitial pneumonia compared to the control group, which exhibited severe lung lesions and lymph node congestion.
  • Antibody Response: Vaccinated pigs showed seroconversion (antibody production) for PRRSV by 14 days post-vaccination and reached peak levels by 28 days. CSFV-specific antibodies also climbed steadily, reaching a blocking rate of over 80%.

Limitations and Future Work

The authors honestly note that the vaccine provided "adequate" rather than "perfect" protection. One out of the five vaccinated pigs still developed a clinical fever for five days after the challenge. This suggests that while the vaccine prevents severe disease and death, it may not provide "sterilizing immunity" (completely preventing infection) against all heterologous strains.

Future research will likely focus on:

  • Long-term Immunity: Determining how long the protection lasts.
  • Broader Challenges: Testing the vaccine against an even wider array of recombinant strains currently circulating in the field.
  • Recombination Risks: As with any live-attenuated vaccine, monitoring the potential for the vaccine strain itself to recombine with wild-type viruses remains a priority for field safety.

Summary updated

Abstract

The recombinant bivalent live vectored vaccine rPRRSV-E2 has been proved to be a favorable genetic engineering vaccine against classical swine fever (CSF) and highly pathogenic porcine reproductive and respiratory syndrome (HP-PRRS). NADC30-like strains have recently emerged in China and caused severe disease, and it is necessary to evaluate the vaccine candidate for the currently circulating viruses. This study established a good challenge model to evaluate the candidate rPRRSV-E2 vaccine in preventing infection with a representative NADC30-like strain (ZJqz21). It was shown that the challenge control piglets displayed clinical signs typical of PRRSV, including a persistent fever, dyspnea, moderate interstitial pneumonia, lymph node congestion, and viremia. In contrast, the rPRRSV-E2 vaccination significantly alleviated the clinical signs, yielded a high level of antibodies, provided adequate protection against challenge with ZJqz21, and inhibited viral shedding and the viral load in target tissues. Our results demonstrated that the recombinant bivalent live vectored vaccine strain rPRRSV-E2 can provide efficient protection against the challenge of heterologous circulating NADC30-like strain and could be a promising vaccine candidate for the swine industry.
BibTeX
@inproceedings{li2022recombinant,
  author = {Liwei Li and Jinxia Chen and Zhengda Cao and Yunlei Cao and Ziqiang Guo and Tong Wu and Yanjun Zhou and Guoxin Li and Yifeng Jiang and Changlong Liu and Lingxue Yu and Sina Qiao and Jiachen Liu and Guangzhi Tong and Fei Gao},
  title = {{Recombinant Bivalent Live Vectored Vaccine Against Classical Swine Fever and HP-PRRS Revealed Adequate Heterogeneous Protection Against NADC30-Like Strain}},
  booktitle = {Frontiers in Microbiology},
  year = {2022},
  doi = {10.3389/fmicb.2021.822749},
}
Figure